EWA
LFCR icon

EverSource Wealth Advisors’s Lifecore Biomedical LFCR Stock Holding History

EverSource Wealth Advisors’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11 Sell
2
-38
-95% -$191 ﹤0.01% 4383
2026
Q1 		$148 Buy
40
+7
+21% +$48 ﹤0.01% 4230
2025
Q4 		$270 Sell
33
-28
-46% -$207 ﹤0.01% 3988
2025
Q3 		$449 Buy
61
+7
+13% +$53 ﹤0.01% 3977
2025
Q2 		$438 Sell
54
-11
-17% -$74 ﹤0.01% 3926
2025
Q1 		$458 Buy
65
+47
+261% +$292 ﹤0.01% 3487
2024
Q4 		$134 Buy
+18
New +$115 ﹤0.01% 3503

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

EverSource Wealth Advisors's LFCR Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Lifecore Biomedical (LFCR) stake by 95% in Q2 2026, selling an estimated $191 and leaving 2 shares worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #4383.

EverSource Wealth Advisors first reported a position in LFCR in Q4 2024 and has held it in 7 quarters since. The position peaked at $458 in Q1 2025. 98 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • EverSource Wealth Advisors held 2 shares of Lifecore Biomedical worth $11 as of Q2 2026.
  • EverSource Wealth Advisors sold 38 Lifecore Biomedical shares in Q2 2026, an estimated $191.
  • Lifecore Biomedical made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4383 holding.
  • EverSource Wealth Advisors first reported a position in Lifecore Biomedical in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Lifecore Biomedical position peaked at $458 in Q1 2025.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.